Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA-cleared AI breast cancer detection suite by iCAD (acquired by RadNet 2025). ProFound AI reads 40M+ mammograms globally with 23% improved detection rate.
Profound AI is the medical imaging AI brand developed by iCAD, a pioneer in cancer detection technology. iCAD's ProFound AI platform applies deep learning to mammography analysis, providing radiologists with AI-powered decision support that identifies suspicious lesions, calculates cancer risk scores, and prioritizes reading worklists based on AI-assessed urgency. The system is designed to function as a second reader — augmenting rather than replacing radiologist judgment — by flagging findings that warrant closer attention and reducing the cognitive load on radiologists reviewing high volumes of routine screening mammograms.\n\nProFound AI has achieved FDA clearance as a medical device for breast cancer detection, enabling its use in clinical radiology workflows across US health systems. The platform processes mammograms in real time, integrating with existing PACS and radiology information systems so it can be deployed without disrupting established workflow. Its clinical validation studies have demonstrated a 23% improvement in cancer detection rate compared to unassisted reads, while simultaneously reducing false positives — a combination that is clinically meaningful and commercially compelling for radiology practices seeking to improve outcomes without adding radiologist time.\n\nProFound AI reads over 40 million mammograms globally, making it one of the most widely deployed FDA-cleared AI systems in radiology. iCAD was acquired by RadNet in 2025, integrating ProFound into one of the largest radiology network operators in the United States. This acquisition significantly expands ProFound's deployment footprint, as RadNet operates hundreds of imaging centers across the US and has the scale to make AI-assisted mammography a standard-of-care offering. The combination of FDA clearance, proven clinical performance, massive global deployment, and integration into a major radiology network positions ProFound AI as a market-defining product in cancer detection AI.
SF YC S23 doctor booking with upfront cost guarantees via ML price prediction; $2.3M Pacific 8/YC seed Dec 2023 solving 57% surprise bills and 38% delayed care competing with Zocdoc for healthcare price transparency booking.
Certainly Health is a San Francisco-based healthcare price transparency marketplace — backed by Y Combinator (S23) with $2.3 million in seed funding in December 2023 from Pacific 8 Ventures, Y Combinator, institutional investors, and angels — providing patients with a doctor booking platform that shows upfront out-of-pocket costs using machine learning to predict and guarantee healthcare spending before appointments, addressing the surprise medical bill crisis where 57% of Americans have received unexpected bills and 38% delay care due to cost uncertainty. Founded in 2023 by Daryl Sew and Kevin Chiu (Stanford graduate, former Uber engineer, and Uber Health founding member who grew that program to $100 million in 2 years), Certainly Health enables patients with insurance to book doctors while seeing the actual cost they will owe — not the sticker price.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.